Thermosensitive hydrogels composed of hyaluronic acid and gelatin as carriers for the intravesical administration of cisplatin

Journal of Pharmaceutical Sciences

Volumn 100, Issue 2, 2011, Pages 655-666

  Chen, Jyh Ping ^a   Leu, Yann Lii ^a   Fang, Chia Lang ^b   Chen, Chao Huang ^a   Fang, Jia You ^a,c  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Cisplatin; Gelatin; Hyaluronic acid; Intravesical delivery; Thermosensitive hydrogel

Indexed keywords

CISPLATIN; GELATIN; HYALURONIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG DELIVERY SYSTEM; DRUG RELEASE; HISTOPATHOLOGY; HYDRATION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT; SCANNING ELECTRON MICROSCOPY;

EID: 78650566926     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22309     Document Type: Article

References (38)

1. Witjes JA, Hendricksen K. 2008. Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: A critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol 53:45-52.
2. Skinner E. 2007. Will a new intravesical chemotherapy agent improve the treatment of non-muscle-invasive bladder cancer? Nat Clin Pract Urol 4:248-249.
3. Schenk-Braat EA, Bangma CH. 2005. Immunotherapy for superficial bladder cancer. Cancer Immunol Immunother 54:414-423.
4. Tyagi P, Wu PC, Chancellor M, Yoshimura N, Huang L. 2006. Recent advances in intravesical drug/gene delivery. Mol Pharm 3:369-379.
5. Fang JY, Huang ZR. 2009. Intravesical drug delivery into the bladder to treat cancers. Curr Drug Deliv 6:227-237.
6. Grabnar I, Bogataj M, Belič A, Logar V, Karba R, Mrhar A. 2006. Kinetic model of drug distribution in the urinary bladder wall following intravesical instillation. Int J Pharm 322:52-59.
7. Shen Z, Shen T, Wientjes MG, O'Donnell MA, Au JLS. 2008. Intravesical treatments of bladder cancer: Review. Pharm Res 25:1500-1510.
8. Tyagi P, Li Z, Chancellor M, De Groat WC, Yoshimura N, Huang L. 2004. Sustained intravesical drug delivery using thermosensitive hydrogel. Pharm Res 21:832-837.
9. Chen JP, Cheng TH. 2009. Preparation and evaluation of thermo-reversible copolymer hydrogels containing chitosan and hyaluronic acid as injectable cell carriers. Polymer 50:107-116.
10. Hahn SK, Kim SJ, Kim MJ, Kim DH. 2004. Characterization and in vivo study of sustained-release formulation of human growth hormone using sodium hyaluronate. Pharm Res 21:1374-1381.
11. Li J, He A, Zheng J, Han CC. 2006. Gelatin and gelatin-hyaluronic acid nanofibrous membranes produced by electrospinning of their aqueous solutions. Biomacromolecules 7:2243-2247.
12. Schoenfeld RH, Belville WD, Jacob WH, Buck AS, Dresner ML, Insalaco SJ, Ward GS. 1983. The effect of dimethyl sulfoxide on the uptake of cisplatin from the urinary bladder of the dog: A pilot study. J Am Osteopath Assoc 82:570-773.
13. Hadaschik BA, ter Borg MG, Jackson J, Sowery RD, So AI, Burt HM, Gleave ME. 2008. Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer. BJU Int 101:1347-1355.
14. Kirchmann H, Pettersson S. 1994. Human urine: Chemical composition and fertilizer use efficiency. Nutr Cycl Agroecosyst 40:149-154.
15. Stevens MP. Ed. 1990. in Polymer Chemistry; New York: Oxford University Press, p. 4.
16. Hirotsu S, Hirokawa Y, Tanaka T. 1987. Volume-phase transitions of ionized N-isopropylacrylamide gels. J Chem Phys 87:1392-1395.
17. Ohya S, Sonoda H, Nakayama Y, Matsuda T. 2001. Thermoresponsive artificial extracellular matrix for tissue engineering: Hyaluronic acid bioconjugated with poly(N-isopropylacrylamide) grafts. Biomacromolecules 2:856-863.
18. Feil H, Bae YH, Feijen J, Kim SW. 1993. Effect of comonomer hydrophilicity and ionization on the lower critical solution temperature of N-isopropylacrylamide copolymers. Macromolecules 26:2496-2500.
19. Chen JP, Cheng TH. 2006. Thermo-responsive chitosan-graft- poly(N-isopropylacrylamide) injectable hydrogel for cultivation of chondrocytes and meniscus cells. Macromol Biosci 6:1026-1039.
20. Balaz EA, Denlinger JL. 1993. Viscosupplementation: A new concept in the treatment of osteoarthritis. J Rheumatol 20:3-9.
21. Lee F, Chung JE, Kurisawa M. 2009. An injectable hyaluronic acid-tyramine hydrogel system for protein delivery. J Control Release 134:186-193.
22. Van Tomme SR, van Nostrum CF, de Smedt SC, Hennink WE. 2006. Degradation behavior of dextran hydrogels composed of positively and negatively charged microspheres. Biomaterials 27:4141-4148.
23. Kashyap N, Kumar N, Kumar MNV Ravi. 2005. Hydrogels for pharmaceutical and biomedical applications. Crit Rev Ther Drug Carrier Syst 22:107-149.
24. Mao JS, Liu HF, Yin YJ, Yao KD. 2003. The properties of chitosan-gelatin membranes and scaffolds modified with hyaluronic acid by different methods. Biomaterials 24:1621-1629.
25. Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios DS. 2002. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release 79:123-135.
26. Huynh DP, Im GJ, Chae SY, Lee KC, Lee DS. 2009. Controlled release of insulin from pH/temperature-sensitive injectable pentablock copolymer hydrogel. J Control Release 137:20-24.
27. Kim MR, Park TG. 2002. Temperature-responsive and degradable hyaluronic acid/Pluronic F-127 composite hydrogels for controlled release of human growth hormone. J Control Release 80:69-77.
28. Peattie RA, Nayate AP, Firpo MA, Shelby J, Fisher RJ, Prestwich GD. 2004. Stimulation of in vivo angiogenesis by cytokine-loaded hyaluronic acid hydrogel implants. Biomaterials 25:2789-2798.
29. Zhang JS, Imai T, Suenaga A, Odagiri M. 2002. Molecular-weight dependent pharmacokinetics and cytotoxic properties of cisplatin complex prepared with chondroitin sulfate A and C. Int J Pharm 240:23-31.
30. Konishi M, Tabata Y, Kariya M, Hosseinkhani H, Suzuki A, Fukuhara K, Mandai M, Takakura K, Fujii S. 2005. In vivo anti-tumor effect of dual release of cisplatin and adriamycin from biodegradable gelatin hydrogel. J Control Release 103:7-19.
31. Yotsuyanagi T, Usami M, Noda Y, Nagata M. 2002. Computational consideration of cisplatin hydrolysis and acid dissociation in aqueous media: Effect of total drug concentrations. Int J Pharm 246:95-104.
32. Hsu SH, Leu YL, Hu JW, Fang JY. 2009. Physicochemical characterization and drug release of thermosensitive hydrogels composed of a hyaluronic acid/Pluronic F127 graft. Chem Pharm Bull 57:453-458.
33. Lu Z, Yeh TK, Tsai M, Au JLS, Wientjes MG. 2004. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin Cancer Res 10:7677-7684.
34. Grabnar I, Bogataj M, Mrhar A. 2003. Influence of chitosan and polycarbophil on permeation of a model hydrophilic drug into the urinary bladder wall. Int J Pharm 256:167-173.
35. Fang JY, Wu PC, Fang CL, Chen CH. 2010. Intravesical delivery of 5-aminolevulinic acid from water-in-oil nano/submicron-emulsion systems. J Pharm Sci 99:2375-2385.
36. Çetinel S, Ercan F, Şirvanci S, Şehirli Ö, Ersoy Y, Şan T, Şener G. 2003. The ameliorating effect of melatonin on protamine sulfate induced bladder injury and its relationship to interstitial cystitis. J Urol 169:1564-1568.
37. Tanii H, Hashimoto K. 1981. Studies on in vitro metabolism of acrylamide and related compounds. Arch Toxicol 48:157-166.
38. Tyagi P, Chancellor MB, Li Z, de Groat WC, Yoshimura N, Fraser MO, Huang L. 2004. Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes. J Urol 171:483-489.